In conclusion, our results showed that TRIM22 expression was abnormally downregulated in gastric cancer and that TRIM22 could inhibit the proliferation and migration of gastric cancer cells by affecting Smad2 protein phosphorylation. Here, TRIM22 is linked to gastric cancer.